Novartis gains access to Regenerex stem cell-based platform with new deal – MedCity News
| MedCity News ZURICH (Reuters) – Swiss drugmaker Novartis AG said on Friday it had signed a licensing and research deal that could boost its ability to develop innovative cell-based therapies for conditions where little treatment is currently available. The maker of … Novartis in Regenerex Stem Cell Deal to Ease Kidney TransplantsBloomberg Novartis strikes stem cell deal to aid transplant patientsFierceBiotech Novartis signs cell therapy deal with RegenerexPMLiVE The Pharma Letter all 7 news articles |
